Please enter a valid month/year e.g. 01/2015

Pick a date between March 2000 and May 2023

Showing 1 to 10 of 470
Title Type Expected publication date
Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897] Technology appraisal guidance Expected publication date:TBC 0
Abatacept for treating active psoriatic arthritis after DMARDs [ID993] Technology appraisal guidance Expected publication date:25 July 2018 20180725
Abdominal aortic aneurysm: diagnosis and management NICE guideline Expected publication date:07 November 2018 20181107
Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147 Technology appraisal guidance Expected publication date:TBC 0
Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy ID1347 Technology appraisal guidance Expected publication date:TBC 0
Abemaciclib with an aromatase inhibitor for untreated advanced hormone-receptor positive, HER2-negative breast cancer ID1227 Technology appraisal guidance Expected publication date:20 February 2019 20190220
Abemaciclib with fulvestrant for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy ID1339 Technology appraisal guidance Expected publication date:TBC 0
Abiraterone for the treatment of metastatic, castrate-resistant prostate cancer following previous cytotoxic chemotherapy TA259 Technology appraisal guidance Expected publication date:TBC 0
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945] Technology appraisal guidance Expected publication date:03 October 2018 20181003
Acute coronary syndromes NICE guideline Expected publication date:07 May 2020 20200507